Literature DB >> 16638574

Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.

Nadine Hanna1, Alexandra Montagner, Wen Hwa Lee, Maria Miteva, Michel Vidal, Michel Vidaud, Béatrice Parfait, Patrick Raynal.   

Abstract

LEOPARD (LS) and Noonan (NS) are overlapping syndromes associated with distinct mutations of SHP-2. Whereas NS mutations enhance SHP-2 catalytic activity, we show that the activity of three representative LS mutants is undetectable when assayed using a standard protein tyrosine phosphatase (PTP) substrate. A different assay using a specific SHP-2 substrate confirms their decreased PTP activity, but also reveals a significant activity of the T468M mutant. In transfected cells stimulated with epidermal growth factor, the least active LS mutants promote Gab1/PI3K binding, validating our in vitro data. LS mutants thus display a reduced PTP activity both in vitro and in transfected cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16638574     DOI: 10.1016/j.febslet.2006.03.088

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  43 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

Review 3.  Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Authors:  Zhi-Hong Yu; Zhong-Yin Zhang
Journal:  Chem Rev       Date:  2017-05-25       Impact factor: 60.622

4.  LEOPARD Syndrome: Clinical Features and Gene Mutations.

Authors:  E Martínez-Quintana; F Rodríguez-González
Journal:  Mol Syndromol       Date:  2012-08-29

5.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

6.  Biochemical and functional characterization of germ line KRAS mutations.

Authors:  Suzanne Schubbert; Gideon Bollag; Natalya Lyubynska; Hoa Nguyen; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Anders Molven; Kevin Shannon
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

7.  Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development.

Authors:  Jason Newbern; Jian Zhong; Rasika S Wickramasinghe; Xiaoyan Li; Yaohong Wu; Ivy Samuels; Natalie Cherosky; J Colleen Karlo; Brianne O'Loughlin; Jamie Wikenheiser; Madhusudhana Gargesha; Yong Qiu Doughman; Jean Charron; David D Ginty; Michiko Watanabe; Sulagna C Saitta; William D Snider; Gary E Landreth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

Review 8.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

9.  Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Authors:  Zhi-Hong Yu; Jie Xu; Chad D Walls; Lan Chen; Sheng Zhang; Ruoyu Zhang; Li Wu; Lina Wang; Sijiu Liu; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2013-03-01       Impact factor: 5.157

10.  Function, regulation and pathological roles of the Gab/DOS docking proteins.

Authors:  Franziska U Wöhrle; Roger J Daly; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2009-09-08       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.